Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 4
2015 1
2016 7
2017 5
2018 7
2019 8
2020 11
2021 25
2022 7
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer.
Fernandes R, Ng TL, Alzahrani MJ, Raphael J, Blanchette P, Black M, Stober C, Pond GR, Cella D, Vandermeer L, Ibrahim M, Clemons M; REaCT Investigators. Fernandes R, et al. Among authors: vandermeer l. Curr Oncol. 2023 Aug 4;30(8):7384-7397. doi: 10.3390/curroncol30080535. Curr Oncol. 2023. PMID: 37623016 Free PMC article. Clinical Trial.
Time to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic Review.
Bradbury M, Hutton B, Beltran-Bless AA, Alzahrani M, Lariviere T, Fernandes R, Ibrahim MF, Cole K, Hilton J, Vandermeer L, Shorr R, Larocque G, Clemons M. Bradbury M, et al. Among authors: vandermeer l. Clin Breast Cancer. 2022 Apr;22(3):e362-e373. doi: 10.1016/j.clbc.2021.10.003. Epub 2021 Oct 9. Clin Breast Cancer. 2022. PMID: 34740542 Free article. Review.
Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT).
Basulaiman B, Awan AA, Fergusson D, Vandermeer L, Arnaout A, Hilton J, Hutton B, Joy AA, Robinson A, Califaretti N, Stober C, Sienkiewicz M, Thavorn K, Clemons M. Basulaiman B, et al. Among authors: vandermeer l. Breast Cancer Res Treat. 2019 Aug;177(1):93-101. doi: 10.1007/s10549-019-05274-0. Epub 2019 May 24. Breast Cancer Res Treat. 2019. PMID: 31127468 Review.
Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review.
Robinson A, Souied O, Bota AB, Levasseur N, Stober C, Hilton J, Kamel D, Hutton B, Vandermeer L, Mazzarello S, Joy AA, Fergusson D, McDiarmid S, McInnes M, Shorr R, Clemons M. Robinson A, et al. Among authors: vandermeer l. Breast Cancer Res Treat. 2018 Oct;171(3):607-620. doi: 10.1007/s10549-018-4868-x. Epub 2018 Jul 4. Breast Cancer Res Treat. 2018. PMID: 29974358 Review.
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.
Beltran-Bless AA, Clemons MJ, Fesl C, Greil R, Pond GR, Balic M, Vandermeer L, Bjelic-Radisic V, Singer CF, Steger GG, Helfgott R, Egle D, Sölkner L, Gampenrieder SP, Kacerovsky-Strobl S, Suppan C, Ritter M, Rinnerthaler G, Pfeiler G, Fohler H, Hlauschek D, Hilton J, Gnant M. Beltran-Bless AA, et al. Among authors: vandermeer l. Eur J Cancer. 2023 Feb;180:108-116. doi: 10.1016/j.ejca.2022.12.003. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36592505 Clinical Trial.
73 results